{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:07:02Z","timestamp":1778188022767,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03150-6","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:34:55Z","timestamp":1746686095000},"page":"3186-3206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dupilumab Efficacy in Children with Atopic Dermatitis with Different Phenotypes and Endotypes: A Case Series"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03346434","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ana B.","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana M.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"3150_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126:417-428.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3150_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad449","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Simpson EL, Silverberg JI, Barbarot S, Eckert L, et al. Burden of atopic dermatitis in paediatric patients: an international cross-sectional study. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad449.","journal-title":"Br J Dermatol"},{"key":"3150_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/pde.13727","volume":"36","author":"EJ Yang","year":"2019","unstructured":"Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: a review. Pediatr Dermatol. 2019;36:66\u201371. https:\/\/doi.org\/10.1111\/pde.13727.","journal-title":"Pediatr Dermatol"},{"key":"3150_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"3150_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpeds.2022.04.027","volume":"246","author":"S Barbarot","year":"2022","unstructured":"Barbarot S, Silverberg JI, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220-226.e5. https:\/\/doi.org\/10.1016\/j.jpeds.2022.04.027.","journal-title":"J Pediatr"},{"key":"3150_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/JAA.S404350","volume":"16","author":"I Neri","year":"2023","unstructured":"Neri I, Galli E, Baiardini I, Picozza M, Rossi AB, Matruglio P, et al. Implications of atopic dermatitis on the quality of life of 6\u201311 years old children and caregivers (PEDI-BURDEN). J Asthma Allergy. 2023;16:383\u201396. https:\/\/doi.org\/10.2147\/JAA.S404350.","journal-title":"J Asthma Allergy"},{"key":"3150_CR7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/bjd.18440","volume":"181","author":"AD Irvine","year":"2019","unstructured":"Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner\u2019s guide. Br J Dermatol. 2019;181:883\u20134.","journal-title":"Br J Dermatol"},{"key":"3150_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/bjd.19885","volume":"185","author":"AR Mulick","year":"2021","unstructured":"Mulick AR, Mansfield KE, Silverwood RJ, Budu-Aggrey A, Roberts A, Custovic A, et al. Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort. Br J Dermatol. 2021;185:526\u201336. https:\/\/doi.org\/10.1111\/bjd.19885.","journal-title":"Br J Dermatol"},{"key":"3150_CR9","unstructured":"Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) highlights of prescribing information. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 9 Dec 2024."},{"key":"3150_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"key":"3150_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83:839\u201346. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.104.","journal-title":"J Am Acad Dermatol"},{"key":"3150_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11\u20138. https:\/\/doi.org\/10.1034\/j.1600-0625.2001.100102.x.","journal-title":"Exp Dermatol"},{"key":"3150_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172:1353\u20137. https:\/\/doi.org\/10.1111\/bjd.13662.","journal-title":"Br J Dermatol"},{"key":"3150_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.1564","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316\u201321. https:\/\/doi.org\/10.1111\/bjd.1564.","journal-title":"Br J Dermatol"},{"key":"3150_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb16953.x.","journal-title":"Br J Dermatol"},{"key":"3150_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1046\/j.1365-2133.2001.03960.x","volume":"144","author":"MS Lewis-Jones","year":"2001","unstructured":"Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants\u2019 dermatitis quality of life index. Br J Dermatol. 2001;144:104\u201310. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.03960.x.","journal-title":"Br J Dermatol"},{"key":"3150_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Willams HC. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326\u201332. https:\/\/doi.org\/10.1111\/bjd.12590.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3150_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2133.1998.02034.x","volume":"138","author":"F Lawson","year":"1998","unstructured":"Lawson F, Reid O. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol. 1998;138(1):107\u201313.","journal-title":"Br J Dermatol"},{"key":"3150_CR19","doi-asserted-by":"crossref","first-page":"13467","DOI":"10.2340\/actadv.v104.13467","volume":"104","author":"AS Paller","year":"2024","unstructured":"Paller AS, Marron SE, Whalley D, et al. Clinically meaningful change threshold in health-related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)\/family. Acta Dermatol Venereol. 2024;104:13467.","journal-title":"Acta Dermatol Venereol"},{"key":"3150_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.36849\/JDD.85852","volume":"24","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Katoh N, Cork MJ, et al. Dupilumab treatment improves lichenification in atopic dermatitis in different age and racial groups. J Drugs Dermatol. 2025;24:167\u201373.","journal-title":"J Drugs Dermatol"},{"key":"3150_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups\u2014variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340\u201357. https:\/\/doi.org\/10.1111\/exd.13514.","journal-title":"Exp Dermatol"},{"key":"3150_CR22","doi-asserted-by":"publisher","first-page":"204062232110029","DOI":"10.1177\/20406223211002979","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:20406223211002980. https:\/\/doi.org\/10.1177\/20406223211002979.","journal-title":"Ther Adv Chronic Dis"},{"issue":"5","key":"3150_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"key":"3150_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Primers"},{"key":"3150_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100519","volume":"14","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Thomsen SF, Lacour JP, et al. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14: 100519. https:\/\/doi.org\/10.1016\/j.waojou.2021.100519.","journal-title":"World Allergy Organ J"},{"key":"3150_CR26","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1111\/all.15822","volume":"78","author":"IK Krohn","year":"2023","unstructured":"Krohn IK, Badloe FMS, Herrmann N, et al. Immunoglobulin E autoantibodies in atopic dermatitis associate with type-2 comorbidities and the atopic march. Allergy. 2023;78:3178\u201392. https:\/\/doi.org\/10.1111\/all.15822.","journal-title":"Allergy"},{"issue":"2 Suppl","key":"3150_CR27","doi-asserted-by":"publisher","first-page":"AB16","DOI":"10.1016\/j.jaci.2023.11.070","volume":"153","author":"B Kim","year":"2024","unstructured":"Kim B, Beck L, Simpson E, et al. Dupilumab reduction of IgE levels and probability of atopic dermatitis flares\u2014analysis of a randomized placebo-controlled 52-week study. J Allergy Clin Immunol. 2024;153(2 Suppl):AB16. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.070.","journal-title":"J Allergy Clin Immunol"},{"key":"3150_CR28","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.2147\/CCID.S391360","volume":"15","author":"L Liu","year":"2022","unstructured":"Liu L, Song G, Song Z. Intrinsic atopic dermatitis and extrinsic atopic dermatitis: similarities and differences. Clin Cosmet Investig Dermatol. 2022;15:2621\u20138. https:\/\/doi.org\/10.2147\/CCID.S391360.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3150_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","volume":"12","author":"E Haddad","year":"2022","unstructured":"Haddad E, Cyr SL, Arima K, et al. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022;12:1501\u201333. https:\/\/doi.org\/10.1007\/s13555-022-00737-7.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03150-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:13Z","timestamp":1750493653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3150"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03150-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana B. Rossi and Adriana M. Mello are employees of and may hold stock and\/or stock options in Sanofi. Joseph Zahn is an employee and shareholder of Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, and applicable regulatory requirements. An independent data and safety monitoring committee conducted blinded monitoring of patient safety data. The local Institutional Review Board or Ethics Committee at each study center oversaw trial conduct and documentation. The study was approved by the Copernicus Group ethics committee. All parents\/guardians provided written informed consent before participating in the trial, including for the publication of clinical photos taken in selected centers. Pediatric patients provided assent according to the Ethics Committee (Institutional Review Board\/Independent Ethics Committee)-approved standard practice for pediatric patients at each participating center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}